Anavex Life Sciences Corp (AVXL)

[powerwalker]

JB, if I remember correctly, Lilly decided in its third attempt to get solanezumab approved to enroll only AD patients who were in the earliest stages of the disease.

This is another indictment against the drug as in Lilly's early findings during this third attempt that the drug is not helping the functional aspect of an AD patient's life. Can there be real cognitive improvement if it does not translate into functional improvement, too?

To add a little intrigue, I was told last fall by the Rush University (Chicago) department managing the solanezumab trial that I qualified for the trial, even though I have no symptoms of the disease.